Radical Prostatectomy News and Research RSS Feed - Radical Prostatectomy News and Research

Radical prostatectomy is surgery to remove all of the prostate gland and some of the tissue around it, to treat prostate cancer.
Researchers evaluate decision aids for patient's choice of localised prostate cancer treatment

Researchers evaluate decision aids for patient's choice of localised prostate cancer treatment

Doctors strive to make treatment decisions together with their patients - but is the decision really shared? According to adjunct professor Kari Tikkinen, shared decision-making isn't easy, and clinicians need help. The international research group led by Tikkinen has studied the decision aids for treatment choice of localised prostate cancer [More]
Research findings lay groundwork for improving treatment assessment for men with prostate cancer

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease. [More]
Cabazitaxel therapy may be more effective in treating prostate cancer

Cabazitaxel therapy may be more effective in treating prostate cancer

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease. [More]
GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined by Decipher) may be optimally managed with observation after radical prostatectomy (prostate surgery), while those with high genomic risk (as determined by Decipher) may be better managed earlier with adjuvant radiotherapy. [More]
Prostate cancer patients with detectable post-operative PSA should receive more aggressive treatment

Prostate cancer patients with detectable post-operative PSA should receive more aggressive treatment

Prostate cancer patients with detectable prostate specific antigen (PSA) following radical prostatectomy should receive earlier, more aggressive radiation therapy treatment, according to a study published in the February 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology. [More]
ArborMetrix's RegistryMetrix analytics platform selected for UNC's urology department

ArborMetrix's RegistryMetrix analytics platform selected for UNC's urology department

ArborMetrix, Inc., a leading provider of cloud-based healthcare analytics solutions, today announced that the Urology Department of the University of North Carolina School of Medicine is using its cloud-based RegistryMetrix analytics platform. [More]
Palmetto GBA issues positive coverage policy for GenomeDx's Decipher prostate cancer test

Palmetto GBA issues positive coverage policy for GenomeDx's Decipher prostate cancer test

GenomeDx Biosciences today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has issued a positive coverage policy through the MolDX Program for the company's Decipher prostate cancer classifier. [More]
Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital. [More]
Researchers develop genetic test to predict prostate cancer recurrence

Researchers develop genetic test to predict prostate cancer recurrence

Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. [More]
New DNA-based test could better predict treatment outcomes for prostate cancer patients

New DNA-based test could better predict treatment outcomes for prostate cancer patients

Researchers at The Ontario Institute for Cancer Research and University Health Network, have identified a new DNA-based test that could be used to better predict how prostate cancer patients will respond to treatment and to prevent relapse. [More]
CMS publishes draft coverage decision for Decipher Prostate Cancer Classifier

CMS publishes draft coverage decision for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical prostatectomy. [More]
Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

For benign gynecologic conditions, robot-assisted surgery involves more complications during surgery and may be significantly more expensive than conventional laparoscopic surgery, according to a study by researchers at Columbia University Medical Center. [More]
Metamark expands prostate cancer test services to include PROGENSAPCA3 assay

Metamark expands prostate cancer test services to include PROGENSAPCA3 assay

Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA® PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay. [More]
Study: US experienced widespread adoption of robot-assisted prostate removal surgery in recent years

Study: US experienced widespread adoption of robot-assisted prostate removal surgery in recent years

A new study reveals that the US has experienced widespread adoption of robot-assisted prostate removal surgery to treat prostate cancer in recent years. The BJU International study also found that while such surgeries are more expensive than traditional surgeries, their costs are decreasing over time. [More]
Study reveals treatment trends for prostate cancer in Japan

Study reveals treatment trends for prostate cancer in Japan

There has been a recent increase in use of radiotherapy in Japanese men newly diagnosed with prostate cancer and a concomitant decrease in use of androgen deprivation therapy, study findings indicate. [More]
Pelvic anatomy changes after prostatectomy linked to LUTS

Pelvic anatomy changes after prostatectomy linked to LUTS

Japanese researchers have identified certain pelvic anatomic features in men who have undergone radical prostatectomy that are associated with specific lower urinary tract symptoms. [More]
Robot-assisted surgery to control prostate cancer effective in controlling disease for 10 years

Robot-assisted surgery to control prostate cancer effective in controlling disease for 10 years

Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital. [More]

Study: Most physicians don't recommend active surveillance for low-risk prostate cancer

Specialists who treat prostate cancer agree that active surveillance is an effective option-yet most don't recommend it when appropriate for their own patients, according to a study in the July issue of Medical Care. The journal is published by Lippincott Williams & Wilkins , a part of Wolters Kluwer Health. [More]
ProMark test for prostate cancer meets primary endpoint

ProMark test for prostate cancer meets primary endpoint

Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint by accurately differentiating between aggressive and non-aggressive forms of prostate cancer at early stages of disease. [More]
Robot-assisted surgery for removing cancerous prostate glands as safe as open surgery, but expensive

Robot-assisted surgery for removing cancerous prostate glands as safe as open surgery, but expensive

Minimally invasive robot-assisted surgery, which has become the main choice for surgically removing cancerous prostate glands during recent years, is as safe as open surgery for Medicare patients over age 65. [More]
Advertisement
Advertisement